Percutaneous Coronary Intervention Clinical Trial
Official title:
PharmacOdynaMic Effects of Cangrelor in PatiEnts wIth Acute or chronIc Coronary Syndrome Undergoing Percutaneous Coronary Intervention (POMPEII Registry)
This prospective registry was designed to carefully investigate the pharmacodynamic (PD) effects of cangrelor in all patients undergoing percutaneous coronary intervention (PCI).
There is huge interest in achieving fast and immediate antiplatelet effect at the time of PCI, particularly in acute myocardial infarction and Cangrelor is an intravenous antagonist of the P2Y12 receptor characterized by rapid, potent, predictable, and reversible platelet inhibition. However, there are limited pharmacodynamic data exploring the effects of this drug in the various clinical settings at the approved dosages and with current gold standard methods for testing platelet reactivity. More importantly, there are no data on rates and predictors of high residual platelet reactivity (HRPR) in patients treated with cangrelor. Therefore the present study aims at building up a large prospective registry of pharmacodynamic data obtained by light transmittance aggregometry (LTA), multiplate analysis and verifynow system in patients undergoing PCI and receiving cangrelor. This study is designed as a single-center prospective registry. Investigators at University Hospital of Naples Federico II will enroll patients, collect blood samples, perform platelet function tests and collect clinical and demographic information. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
| Not yet recruiting |
NCT05669222 -
The FAVOR V AMI Trial
|
N/A | |
| Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
| Recruiting |
NCT05240781 -
Zotarolimus vs Sirolimus Eluting Stent in High Bleeding Risk
|
N/A | |
| Recruiting |
NCT03378934 -
Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention
|
Phase 4 | |
| Not yet recruiting |
NCT06025071 -
Residual Inflammatory Risk-Guided colcHicine in Elderly Trial
|
Phase 4 | |
| Withdrawn |
NCT04043091 -
Coronary Angiography in Critically Ill Patients With Type II Myocardial Infarction
|
N/A | |
| Completed |
NCT02837744 -
Studying Hemostatic Effect of Axiostat® Dressing on Radial Access After Percutaneous Procedure
|
||
| Completed |
NCT03085823 -
The All-comers Sirolimus-coated Balloon European Registry
|
||
| Completed |
NCT02044146 -
A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk
|
Phase 2/Phase 3 | |
| Completed |
NCT03131271 -
Effect of Ice Bag Application to Femoral Region on Pain in Patients Undergoing Percutaneous Coronary Intervention
|
N/A | |
| Completed |
NCT01135667 -
Prasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI
|
Phase 4 | |
| Completed |
NCT01156571 -
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)
|
Phase 3 | |
| Unknown status |
NCT00751491 -
Clopidogrel Versus Adenosin in Non Urgent Percutaneous Coronary Intervention (PCI)
|
Phase 3 | |
| Completed |
NCT00725868 -
Blood Endothelium Biomarkers to Predict Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention
|
N/A | |
| Completed |
NCT03708588 -
Chewed Versus Integral Pill of Ticagrelor
|
Phase 4 | |
| Completed |
NCT04163393 -
R-One Efficiency For PCI Evolution With Robotic Assistance
|
N/A | |
| Recruiting |
NCT05554588 -
Intrathrombus Thrombolysis Versus Aspiration Thrombectomy During Primary PCI
|
N/A | |
| Recruiting |
NCT06080919 -
Plaque Modification And Impact On Microcirculatory Territory After Drug-Coated Balloon Percutaneous Coronary Intervention (PLAMI).
|
N/A | |
| Recruiting |
NCT05353140 -
LAAO Versus NOAC in Patients With AF and PCI
|
N/A |